ASX Share rice
Fri 07 Aug 2020 - 01:57:am (Sydney)

IPD Share Price

IMPEDIMED LIMITEDIPDHealth Care Equipment & Services

IPD Company Information

Name:

ImpediMed Limited

Sector:

Healthcare

Industry:

Medical Devices

GIC Industry:

Health Care Equipment & Supplies

GIC Sub Industry:

Health Care Equipment

Address:

50 Parker Court Pinkenba QLD Australia 4008

Phone:

61 7 3860 3700

Full Time Employees:

67

MD, CEO, Pres & Exec. Director:

Mr. Richard Carreon

Sr. VP of Operations & Strategic Planning:

Mr. David Michae Adams B.Sc., J.D., BSc

Chief Technology Officer:

Mr. Shashi Tripathi

Sr. VP of R&D and Technology:

Mr. Dennis Schlaht

Sr. VP of Medical Affairs:

Ms. Catherine Kingsford

Company Overview:

ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.

IPD Share Price Information

Shares Issued:

1.01B

Market Capitalisation:

$82.42M

Revenue (TTM):

$5.19M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.064

Operating Margin (TTM):

$-5.33

Return On Assets (TTM):

$-0.62

Return On Equity (TTM):

$-1.11

Quarterly Revenue Growth (YOY):

0.575

Gross Profit(TTM):

$2.90M

Diluted Earnings Per Share (TTM):

$-0.057

IPD CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-1,765,000

Change To Liabilities:

$451K

Total Cashflow From Investing Activities:

$-1,765,000

Net Income:

$-24,123,000

Total Cash From Operating Activities:

$-19,588,000

Depreciation:

$234K

Other Cashflow From Investing Activities:

$459K

Change To Inventory:

$690K

Change To Account Receivables:

$609K

Sale Purchase Of Stock:

$-18,000

Capital Expenditures:

$2.22M

IPD Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-23,945,000

Net Income:

$-24,123,000

Gross Profit:

$2.85M

Operating Income:

$-27,012,000

Income Tax Expense:

$51K

Total Revenue:

$4.10M

Total Operating Expenses:

$29.86M

Cost Of Revenue:

$1.25M

IPD Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$2.79M

Total Liabilities:

$6.80M

Total Stockholder Equity:

$15.79M

Other Current Liabilities:

$520K

Total Assets:

$22.58M

Common Stock:

$219.73M

Other Current Assets:

$497K

Retained Earnings:

$-228,717,000

Other Liabilities:

$135K

Good Will:

$2.58M

Cash:

$11.33M

Total Current Liabilities:

$6.66M

Property - Plant & Equipment:

$188K

Net Tangible Assets:

$10.41M

Long-Term Investments:

$45K

Total Current Assets:

$16.97M

Net Receivables:

$800K

Short-Term Investments:

$5.61M

Inventory:

$1.12M

Accounts Payable:

$2.09M

Non Currrent Assets (Other):

$5.61M

Short-Term Investments:

$5.61

Non Current Liabilities Total:

$135K

IPD Share Price History

IPD News

09 Jun, 2020
24 Apr, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
24 Feb, 2020
ImpediMed Limited's (ASX:IPD): ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells...
13 Feb, 2020
ImpediMed Limited (ASX.IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), is pleased to report that the NCCN Clinical Practice Guidelines for Breast Cancer (NCCN Guidelines®) were updated with new recommendations for early detection and diagnosis of lymphedema to achieve optimal management. Additionally, healthcare providers are now encouraged to consider pretreatment baseline measurements for patients with lymphedema risk factors.
01 Feb, 2020
24 Jan, 2020
20 Jan, 2020
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So spare a...
11 Dec, 2019
ImpediMed Limited (ASX.IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), recently announced the issuance of a further 510(k) clearance for SOZO® by the U.S. Food and Drug Administration (FDA). SOZO is the first device to gain FDA clearance for use as an aid in the assessment of Protein Calorie Malnutrition.
05 Dec, 2019
If you own shares in ImpediMed Limited (ASX:IPD) then it's worth thinking about how it contributes to the volatility...
28 Oct, 2019
In 2012 Rick Carreon was appointed CEO of ImpediMed Limited (ASX:IPD). This report will, first, examine the CEO...
23 Oct, 2019
Company launches website focused on education and prevention CARLSBAD, Calif. and BRISBANE, Australia , Oct. 23, 2019 /PRNewswire/ --  ImpediMed Limited (ASX: IPD), a global provider of medical technology ...
25 Sep, 2019
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
09 Aug, 2019
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...